Shares of Eli Lilly & Co. LLY advanced 2.48% to $733.29 Thursday, on what proved to be an all-around great trading session ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...

BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET. Company Participants. Lucas Montarce - CFO Mike Czapar - SVP, IR. Confe ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

U.S. equities were mixed at midday, with the Dow Jones Industrial Average and S&P 500 slightly higher and the Nasdaq ...

First-line treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival compared with lenvatinib ...

Adults with a mental illness experienced weight loss and glycemic benefits with use of a GLP-1 without worsening of mental ...

President Donald Trump imposed a minimum tariff of 10% on almost all countries, before later suspending the measures ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

While the early week buzz centered around the U.S.-China trade agreement, another critical development unfolded quietly but ...

CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...

American Medical Association named John J. Whyte, MD, MPH as its next CEO and EVP, effective July 1. Centivo hired Sarah ...